Hospital Universitario Niño Jesús HUNJ

HUNJHospital Universitario Niño Jesús is a public institution of “Servicio Madrileño de Salud” (SERMAS), which provides specialized health services in the specialty of Pediatrics and Specific Areas to pediatric patients (0-18 years) of Madrid and all regions of Spain, in line with current regulations and legislation. Its commitments are providing quality pediatric care oriented health outcomes, specialized health training, and biomedical research with national and international recognition. The hospital gave birth to the pediatric specialty in Spain, since its founding in 1877, and became a pediatric reference health center nationwide. Scientific and research work, backed by the prestige of the practitioners of best clinical practice has been strengthened in the last years thanks to the launch of the Foundation for Biomedical Research Hospital Universitario Niño Jesus. The Foundation is part of the IIS-Princesa.

Biomedical Research Foundation of Hospital de La Princesa (FIBHULPR) is the third party of HUNJ. It manages research projects at Hospital Universitario de La Princesa (HULPR), also Hospital Universitario Niño Jesús, Hospital Universitario Santa Cristina and Universidad Autonoma, all of them partners of our Health Research Institute La Princesa (IIS-Princesa).

This IIS-Princesa was created on 2009, as an association of public health care centres in Madrid (Hospital Universitario de La Princesa, Hospital Infantil Universitario Niño Jesús, Hospital Santa Cristina and the FIBHULPR) and the Universidad Autónoma de Madrid (UAM). The institution has more than 450 researchers, which cover almost all medical fields.

Infrastructure/technical equipment

Hospital Universitario Niño Jesús is actually integrated in the network of Madrid Health System through SERMAS and has all IT infrastructure and facilities for telemedicine currently working in the network. It also counts with the supervision of the Office for Security of IT Systems at the Madrid Health Department.  “Servicio Madrileño de Salud (SERMAS) is the administrative and management structure that integrates every public hospital and other public health services of the Madrid Regional Health System. It is the legal representative (beneficiary) of the public hospital contributing to the project and has delegated authority to the relevant Hospital Foundation which will handle the financial and administrative aspects of the Hospital’s involvement in the project.

It has 51 research groups, which focus their activities on three main areas: (i) Cellular and Molecular Etiopathogenic Mechanisms in Inflammatory and Autoimmune Diseases; (ii) Neurotransmission, Pharmacological neuroprotection and neurodegenerative and neuropsychiatric diseases; and (iii) Advanced Therapies and Individualized Medicine. Furthermore IIS-Princesa offers a Innovation and a Methodological support Unit which provide support to the research groups.

Facilities include proteomic, electron microscopy; genomic, flow cytometry, videomicroscopy and animal facilities. The Biological Therapies Unit the first in Inflammatory Diseases in Spain. A Biobank that gives researchers access to a potential store of 150,000 samples. A Central Unit for Clinical Research and Clinical Trials (UCICEC), and a controlled environment production area (White room).

Hospital Universitario Niño Jesús is a children’s hospital. This characteristic represents an advantage over the previous partner since it is likely that a child with some illness goes to a pediatric hospital in case of need. Moreover, Hospital Universitario Niño Jesús is one of the three Spanish children’s hospitals, with a high level of specialization. This allows to easily simulating the exchange of clinical information through telemedicine about children with medical complexities.

Relevant EU and National Project

  • Non-pharmacological treatment for neuropathic pain induced by vincristine in children with leukemia. Fundación Mutua Madrileña, 2014-2016. 22135 €.
  • A role for Bmp4 in childhood acute lymphoblastic leukemia: prognostic factor and function in relapse. Fundación Uno entre Cienmil, 2014-2016. 75000 €.
  • Severe, early-onset childhood obesity: metabolic, hormonal, genetic, genomic and metabolomic basis. ISCIII, 2014-2017. 249629 €.
  • Study of the mechanisms of action of Celyvir therapy in childhood tumors: towards optimizing clinical results. ISCIII, 2014-2017. 112003 €.
  • Identification and validation of biomarkers of childhood leukemic relapses. ISCIII, 2014-2017. 125180 €.
  • Robotic platform for rehabilitation and gait training in patients with cerebral palsy. Ministry of Economy and Innovation, 2014-2017. 121680 €.
  • Application of Modern Biology in the Development of Improved Diagnostic Tools and More Efficient Therapies for Patients with Mutated Fanconi Anemia/BRCA Genes (FANCOGENE). ISCIII, 2012-2017. 34942 €.
  • Anatomic evaluation by PET-FDG image fusion and 3 Tesla MRI in children with refractory epilepsy. ISCIII, 2014-2017. 102815 €.
  • A new generation of more effective and safer cellular medicines. Madrid Regional Council of Economy, 2012-2016. 121440 €.
  • Monogenic Diabetes in Children. ISCIII, 2013-2017. 121500 €.
Share